Cargando...

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases

Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncol Res
Autores principales: Xu, Jianping, Liu, Xiaoyan, Yang, Sheng, Shi, Yuankai
Formato: Artigo
Lenguaje:Inglês
Publicado: Cognizant Communication Corporation 2020
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851530/
https://ncbi.nlm.nih.gov/pubmed/31610827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504019X15707896762251
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!